Pachmann GmbH&Co. KG participated in the ACNEM Annual Conference 2025, held on July 4th–5th,2025 in Melbourne, Australia, under the theme "Integrative Cancer Therapies". The two-day event covered a broad spectrum of topics in cancer care-from evidence-based strategies in cancer biology to supportive therapies, nutritional medicine, lifestyle-related factors and innovative new treatment approaches.
As part of the conference, Pachmann GmbH&Co. KG presented the poster:
"Tumorspheres Derived from Circulating Cancer Stem Cells as Surrogate Markers of Tumor Aggressiveness and Metastatic Burden in Breast Cancer" [M. Pizon, D. Schott, J. Fluhrer, K. Pachmann, 2025]
and showcased its maintrac® and stemtrac® methods for monitoring circulating tumor cells and cancer stem cells.
The poster highlights the role of circulating cancer stem cells(cCSCs) in metastasis, therapy resistance and relapse in breast cancer. In a study involving 98 breast cancer patients(stages I–IV), a tumorsphere assay was conducted using peripheral blood samples analyzed with the stemtrac® method. The results showed significant correlations between tumorsphere counts and disease stage, metastatic status, as well as markers of tumor aggressiveness such as HER2/neu-positivity, elevated Ki-67 index and higher histological grade.